🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Lee Ainslie’s REGN Holdings & Trades

First Buy
Q3 2020
Duration Held
7 Quarters
Largest Add
Q3 2026
+1,824 Shares
Current Position
1,824 Shares
$1.38 M Value

Lee Ainslie's REGN Position Overview

Lee Ainslie (via Maverick Capital LTD) currently holds 1,824 shares of Regeneron Pharmaceuticals, Inc. (REGN) worth $1.38 M, representing 0.01% of the portfolio. First purchased in 2020-Q3, this short-term holding has been held for 7 quarters.

Based on 13F filings, Lee Ainslie has maintained this position in REGN for several quarters, showing initial confidence in the investment. Largest addition occurred in Q3 2026, adding 1,824 shares. Largest reduction occurred in Q1 2024, reducing 1,758 shares.

Analysis based on 13F filings available since 2013 Q2

Lee Ainslie's Regeneron Pharmaceuticals (REGN) Holding Value Over Time

Track share changes against reported price movement

Quarterly Regeneron Pharmaceuticals (REGN) Trades by Lee Ainslie

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q3 2026 +1,824 New Buy 1,824 $758.27
Q1 2024 -1,758 Sold Out 0 $0.00
Q4 2023 +1,758 New Buy 1,758 $878.29
Q4 2021 -490 Sold Out 0 $0.00
Q3 2021 +490 New Buy 490 $606.12
Q4 2020 -588 Sold Out 0 $0.00
Q3 2020 +588 New Buy 588 $559.52

Lee Ainslie's Regeneron Pharmaceuticals Investment FAQs

Lee Ainslie first purchased Regeneron Pharmaceuticals, Inc. (REGN) in Q3 2020, acquiring 588 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Lee Ainslie has held Regeneron Pharmaceuticals, Inc. (REGN) for 7 quarters since Q3 2020.

Lee Ainslie's largest addition to Regeneron Pharmaceuticals, Inc. (REGN) was in Q3 2026, adding 1,824 shares worth $1.38 M.

According to the latest 13F filing for Q3 2026, Lee Ainslie's firm, Maverick Capital LTD, owns 1,824 shares of Regeneron Pharmaceuticals, Inc. (REGN), valued at approximately $1.38 M.

As of the Q3 2026 filing, Regeneron Pharmaceuticals, Inc. (REGN) represents approximately 0.01% of Lee Ainslie's publicly disclosed stock portfolio, making it one of their key holdings.

Lee Ainslie's peak holding in Regeneron Pharmaceuticals, Inc. (REGN) was 1,824 shares, as reported at the end of Q3 2026.